# The Placenta in Gestational Diabetes: An Integrated Review on Metabolic Pathways, Genetic, Epigenetic and Ultrasound Biomarkers for Clinical Perspectives

## TL;DR

This paper reviews how genetic, epigenetic, and non-invasive biomarkers can help detect and manage gestational diabetes early, aiming to improve pregnancy outcomes.

## Contribution

The paper integrates current knowledge on metabolic pathways and biomarkers for gestational diabetes, highlighting novel non-invasive diagnostic approaches.

## Key findings

- Genetic and epigenetic factors influence susceptibility to gestational hyperglycemia and metabolic dysregulation.
- Non-invasive biomarkers like cell-free DNA and microRNAs show promise for early detection of diabetic pregnancies.
- Integrating molecular data can improve risk stratification and enable personalized management strategies.

## Abstract

Pregnancies complicated by diabetes, including pregestational and gestational diabetes mellitus, are associated with increased maternal and fetal morbidity. Early identification of at-risk pregnancies is crucial for timely intervention and improved outcomes. Emerging evidence highlights the interplay of genetic predisposition, epigenetic modifications, and non-invasive biomarkers in the early detection of diabetic pregnancies. Genetic factors influencing insulin signaling, glucose metabolism, and pancreatic β-cell function may contribute to susceptibility to gestational hyperglycemia. Concurrently, epigenetic alterations, such as DNA methylation and histone modifications in maternal and placental tissues, have been linked to dysregulated metabolic pathways and adverse pregnancy outcomes. Non-invasive biomarkers, including circulating cell-free DNA and microRNAs in maternal blood, show promise for early diagnosis by offering a safer and more practical alternative to invasive testing. Integrating genetic, epigenetic, and molecular marker data could enhance risk stratification and enable personalized monitoring and management strategies. This review synthesizes current knowledge on the molecular underpinnings of diabetic pregnancies, evaluates the potential of emerging biomarkers for early diagnosis, and discusses the challenges and future perspectives for translating these findings into clinical practice. Understanding these mechanisms may pave the way for precision medicine approaches, ultimately improving maternal and neonatal outcomes in pregnancies affected by diabetes.